I would like to bring attention to an important recent study (Gessler et al. 2017) in which genetic engineering placed a genetic construct into the wrong cell at the right time and was thus able to rescue murine Canavan disease (CD). Hopefully, this letter will provide some additional context for evaluating this remarkable finding. CD is a rare human inborn error of metabolism in which oligodendrocyte aspartoacylase (ASPA) is inactive, with only several hundred human CD cases worldwide at any given time. Although the precise roles of ASPA and N-acetyl-L-aspartate (NAA), its natural substrate, are still debated, they are clearly important in that they are present in every human brain thus far examined, save one (Martin et al. 2001) , and in almost every other vertebrate brain examined.
I would like to bring attention to an important recent study (Gessler et al. 2017) in which genetic engineering placed a genetic construct into the wrong cell at the right time and was thus able to rescue murine Canavan disease (CD). Hopefully, this letter will provide some additional context for evaluating this remarkable finding. CD is a rare human inborn error of metabolism in which oligodendrocyte aspartoacylase (ASPA) is inactive, with only several hundred human CD cases worldwide at any given time. Although the precise roles of ASPA and N-acetyl-L-aspartate (NAA), its natural substrate, are still debated, they are clearly important in that they are present in every human brain thus far examined, save one (Martin et al. 2001) , and in almost every other vertebrate brain examined.
CD is a spongiform leukodystrophy characterized by earlyonset megalocephaly and a progressive loss of function, generally leading to early mortality. Important characteristics of CD are the buildup of high concentrations of NAA in brain, formation of edematous vacuoles, and continuous presence of high concentrations of NAA in urine. ASPA and NAA are part of a unique tricellular metabolic system in the brain wherein NAA is made in neurons from acetyl Co-enzyme A and L-aspartate by NAA synthase and is then used to synthesize an L-glutamate (Glu) adduct, N-acetylaspartylglutamate (NAAG), via NAAG synthase (Baslow 2000) . Neurons cannot further metabolize either of these substances and for hydrolysis are released to extracellular fluid (ECF). NAAG is targeted to the metabotropic glutamate receptor 3 (mGluR3) on the surface of astrocytes and upon docking is cleaved into Glu and NAA by NAAG peptidase. The NAA product cannot be further hydrolyzed by astrocytes, since they do not express ASPA (Baslow et al. 1999) , and is thus released to oligodendrocytes, which do express this enzyme. This unique system requires coordinated functioning of four enzymes, two anabolic and two catabolic, distributed in three cell types and a specific receptor for its completion in order to maintain normal brain function. The absence of ASPA activity results in CD, and the absence of NAA synthase activity results in hypoacetylaspartia where neither NAA nor NAAG are produced (Waime et al. 2010) . Both conditions display profound, clinically observed, negative consequences. While the function of this system is as yet unclear, a recent hypothesis suggests that the role of the NAAG-mGluR3-NAAG peptidase complex is to communicate a neuron's ongoing requirements for energy and oxygen to astrocytes that in turn signal the vascular system to increase focal blood flow (Baslow and Guilfoyle 2016) .
Previous genetic engineering attempts to treat human CD have been aimed at oligodendrocytes, the cells that naturally express ASPA. As reported (Gessler et al. 2017) , there has been a breakthrough in treatment of murine CD using a novel gene therapy approach that inserts the normal gene into astrocytes rather than into oligodendrocytes. This appears to be of major importance in rescuing CD in that ASPA activity is introduced at the end of the NAAG metabolic chain within the same cell and after it has activated the mGluR3 astrocyte receptor. It had been hypothesized that astrocytes were the cause of the spongiform leukodystrophy component in CD. This is because NAAG liberated at nodes of Ranvier in white matter would be hydrolyzed by astrocytes forming NAA, which in the case of CD could not be hydrolyzed by oligodendrocytes. Consequently, NAA would build up in restricted ECF space at these nodes, penetrating between existing oligodendrocyte myelin layers and producing an osmotic effect resulting in demyelination and the formation of spongiform vacuoles that form between myelin layers in this disease (Baslow and Guilfoyle 2009) .
The breakthrough treatment reported (Gessler et al. 2017 ) is novel in that it bypasses this problem by inserting the engineered ASPA gene directly into astrocytes, which do not normally express this enzyme (Baslow et al. 1999 ). This occurs at the site of NAA production in astrocytes in both gray and white matter, thus eliminating any buildup in ECF from this or any other source. It also supports the notion that the cause of the spongiform leukodystrophy in CD is due to NAA buildup resulting from hydrolysis of NAAG at nodes of Ranvier by astrocytes. If this treatment can be successfully developed for human CD, it would constitute an unusual genetic engineering success as a result of placing an engineered enzyme construct in the wrong cell but at the right time to treat CD, as well as a potential model for treating other human metabolic diseases by redirecting their metabolic processes.
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